NCT01588522View on ClinicalTrials.gov

Compound 31543 (Calcitriol, USP) in Patients Receiving Taxane-based Chemotherapy Regimens for the Treatment of Chemotherapy-Induced Alopecia

PHASE1CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

September 17, 2012

Primary Completion Date

February 16, 2017

Study Completion Date

February 16, 2017

Conditions
Chemotherapy-Induced Alopecia
Interventions
DRUG

Compound 31543 Calcitriol 5 μg/mL

5 μg/mL Topical Solution

DRUG

Compound 31543 Calcitriol 10 μg/mL

10 μg/mL Topical Solution

DRUG

Compound 31543 Calcitriol 20 μg/mL

20 μg/mL Topical Solution

DRUG

Compound 31543 Calcitriol 40 μg/mL

40 μg/mL Topical Solution

DRUG

Compound 31543 Calcitriol 60 ug/mL

60 ug/mL Topical Solution

DRUG

Compound 31543 Calcitriol 80 μg/mL

80 μg/mL Topical Solution

Trial Locations (2)

10022

Memorial Sloan-Kettering Cancer Center, New York

90048

Samuel Oschin Comprehensive Cancer Institute Cedars-Sinai, Los Angeles

All Listed Sponsors
lead

BPGbio

INDUSTRY

NCT01588522 - Compound 31543 (Calcitriol, USP) in Patients Receiving Taxane-based Chemotherapy Regimens for the Treatment of Chemotherapy-Induced Alopecia | Biotech Hunter | Biotech Hunter